Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon.,Journal of Antimicrobial Chemotherapy

当前位置： X-MOL 学术 › J. Antimicrob. Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon.
Journal of Antimicrobial Chemotherapy ( IF 3.9 ) Pub Date : 2020-09-20 , DOI: 10.1093/jac/dkaa383
Benjamin M Wenk ₁ , Herbert A Mbunkah _{1,

2} , Ndi N Nsanwe ₃ , Eyongetah T Mbu ₃ , Lydia M Besong ₄ , Bella A Sama ₅ , Emmanuel Orock ₆ , Christine Leemann ₁ , Karin J Metzner _{1,

7}

Affiliation

In Cameroon, the integrase (IN) strand transfer inhibitor (INSTI) dolutegravir was recently introduced for the treatment of HIV-1 infection. Since pretreatment HIV-1 drug resistance can jeopardize the success of ART, and considering the high heterogeneity of circulating HIV-1 subtypes in Cameroon, we investigated the prevalence of pretreatment HIV-1 resistance to INSTIs.

中文翻译：

在喀麦隆，未接受过抗逆转录病毒治疗的HIV-1感染者中整合酶链转移抑制剂抗性突变的发生率。

在喀麦隆，最近引入了整合酶（IN）链转移抑制剂（INSTI）dolutegravir用于治疗HIV-1感染。由于预处理HIV-1的耐药性可能会危害ART的成功，并且考虑到喀麦隆循环中HIV-1亚型的高度异质性，我们研究了预处理HIV-1对INSTIs的耐药性。

更新日期：2020-09-21

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11